Large indirect Sofgen Pharma (PRCWF) stake and warrant disclosed in Form 3

Rhea-AI Filing Summary

Sofgen Pharma S.A. director and 10% owner Fernando Sebastian Moreira Muniz filed an initial statement of beneficial ownership. The filing reports indirect holdings through Becaril S.A., which Becaril beneficially owns 305,309,149 Ordinary Shares of Sofgen Pharma and a warrant to purchase 19,800,411 Ordinary Shares with an exercise price of $0.0631 per share expiring on April 9, 2035. These entries reflect existing positions rather than new market transactions.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Moreira Muniz Fernando Sebastian

Role Director, 10% Owner

Type	Security	Shares	Price	Value
holding	Warrant to Purchase Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Warrant to Purchase Ordinary Shares — 19,800,411 shares (Indirect, By Becaril S.A.); Ordinary Shares — 305,309,149 shares (Indirect, By Becaril S.A.)

Footnotes (1)

1. Represents Ordinary Shares beneficially owned by Becaril S.A. ("Becaril"), an entity controlled by Mr. Moreira Muniz. Represents a warrant to purchase Ordinary Shares beneficially owned by Becaril, an entity controlled by Mr. Moreira Muniz.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Moreira Muniz Fernando Sebastian

(Last) (First) (Middle)

11600 MIRAMAR PARKWAY, SUITE 300

(Street)

MIRAMAR FLORIDA 33025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Sofgen Pharma S.A. [ PROC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	305,309,149	I	By Becaril S.A.(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant to Purchase Ordinary Shares	04/09/2025	04/09/2035	Ordinary Shares	19,800,411	$0.0631	I	By Becaril S.A.(2)

Explanation of Responses:

1. Represents Ordinary Shares beneficially owned by Becaril S.A. ("Becaril"), an entity controlled by Mr. Moreira Muniz.

2. Represents a warrant to purchase Ordinary Shares beneficially owned by Becaril, an entity controlled by Mr. Moreira Muniz.

Remarks:

See Exhibit 24 - Power of Attorney.

	/s/ Freddy Andres Lozano Reyes, attorney-in-fact.	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Form 3 filing by Fernando Sebastian Moreira Muniz disclose for PRCWF?

The Form 3 shows that Fernando Sebastian Moreira Muniz, a director and 10% owner, indirectly beneficially owns Sofgen Pharma shares through Becaril S.A. It lists large Ordinary Share holdings and a warrant position but does not report any new purchase or sale transactions.

How many Sofgen Pharma (PRCWF) Ordinary Shares are beneficially owned through Becaril S.A.?

The filing reports that Becaril S.A., an entity controlled by Fernando Sebastian Moreira Muniz, beneficially owns 305,309,149 Ordinary Shares of Sofgen Pharma S.A. This stake is reported as an indirect holding and forms part of his status as a ten percent owner.

What warrant position related to PRCWF is reported in this Form 3?

The Form 3 discloses a warrant beneficially owned by Becaril S.A. to purchase 19,800,411 Sofgen Pharma Ordinary Shares. The warrant has an exercise price of $0.0631 per share and an expiration date of April 9, 2035, reflecting a sizable derivative position.

Is the ownership reported in the Sofgen Pharma (PRCWF) Form 3 direct or indirect?

All positions in the Form 3 are reported as indirect holdings. They are held by Becaril S.A., which is controlled by Fernando Sebastian Moreira Muniz. The filing clarifies that both the Ordinary Shares and the warrant are beneficially owned through this entity.

Does the Sofgen Pharma (PRCWF) Form 3 show any insider buying or selling activity?

The Form 3 does not show insider buying or selling activity. Instead, it records existing beneficial ownership positions in Ordinary Shares and a warrant held indirectly through Becaril S.A., serving as an initial ownership statement rather than a record of recent trades.